What the studies show
Kills bacteria in vitro and in animal models; no human trial has tested LL-37 as an anti-infective in any route.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Reviews of LL-37 biology in infection, wound repair and autoimmunity.VariousPreclinical mechanism; no systemic human data.
In context
LL-37 is the only cathelicidin peptide humans make — a 37-amino-acid antimicrobial produced by skin, gut and immune cells that kills bacteria and signals inflammation and repair. The human evidence is two randomised trials of a topical gel on venous leg ulcers: a 34-patient phase 2a that found faster healing, and a 148-patient phase 2b that did not, except in a subgroup of large wounds. Nothing supports the injected 'immune' or 'anti-inflammatory' uses sold online, and injected LL-37 is pro-inflammatory in the laboratory.
LL-37 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is LL-37 proven to help with antimicrobial action in people?
What studies are behind the grade?
Is LL-37 approved for this?
Other outcomes for LL-37
- CVenous leg ulcer healing (topical)2 RCTs (n=34, n=148)
- DSystemic 'immune support' or anti-inflammatory use0
- CSafety (topical)adverse2 RCTs
Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →